Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZYNE
Previous Symbol
CUSIPN/A
Phone484-581-7505
Debt
Debt-to-Equity RatioN/A
Current Ratio7.95
Quick Ratio7.95
Price-To-Earnings
Trailing P/E Ratio-1.88
Forward P/E Ratio-1.62
P/E GrowthN/A
Sales & Book Value
Annual Sales$10,000.00
Price / Sales8,215.58
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.50 per share
Price / Book1.04
Profitability
EPS (Most Recent Fiscal Year)($2.48)
Net Income$-32,010,000.00
Net MarginsN/A
Return on Equity-74.82%
Return on Assets-63.35%
Miscellaneous
Employees22
Outstanding Shares17,630,000
Market Cap$84.61 million
OptionableOptionable
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions
What is Zynerba Pharmaceuticals' stock symbol?
Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."
How were Zynerba Pharmaceuticals' earnings last quarter?
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) posted its earnings results on Thursday, November, 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.70) by $0.23. View Zynerba Pharmaceuticals' Earnings History.
When is Zynerba Pharmaceuticals' next earnings date?
What price target have analysts set for ZYNE?
6 Wall Street analysts have issued 12-month price targets for Zynerba Pharmaceuticals' stock. Their forecasts range from $15.00 to $25.50. On average, they expect Zynerba Pharmaceuticals' share price to reach $20.10 in the next year. This suggests a possible upside of 331.3% from the stock's current price. View Analyst Price Targets for Zynerba Pharmaceuticals.
What is the consensus analysts' recommendation for Zynerba Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynerba Pharmaceuticals.
What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?
Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (11/21/2018)
- 2. Cantor Fitzgerald analysts commented, "We rate ZYNE Overweight. The company is developing a transdermally administered cannabidiol (CBD) gel, ZYN-002, for the treatment of behavioral symptoms associated with FXS, and seizures in developmental and epileptic encephalopathies (DEE) and adult refractory focal epilepsy (arfe). We focus our valuation on FXS, where we are encouraged by the open-label, long-term data, with meaningful and durable improvements that we see having predictive value for the pbo-controlled pivotal CONNECT-FX trial." (10/2/2018)
- 3. Canaccord Genuity analysts commented, "We maintain our BUY rating on KMPH shares given what we see as a potentially positive product profile for KP415 once all the data kinks are worked out. We’d be buyers on any KMPH weakness on this data read." (7/5/2018)
- 4. HC Wainwright analysts commented, "We do not see this as a material negative, as we never included ZYN001 for Tourette’s or any other indication in our estimates or valuation. Our valuation is entirely based on Orphan Designated ZYN002 transdermal cannabidiol (CBD) gel for Fragile X Syndrome (FXS), entering Phase 3 shortly, with upside optionality from ongoing work in refractory and rare epilepsies. In fact, we view this early-stage ZYN001 termination as a sign of responsible drug development and note that it actually undermines the most cynical ZYN002 bear-argument we’ve heard: that the CBD doesn’t even get into the blood. Zynerba has not released ZYN002 PK data for intellectual property reasons in a competitive CBD field, but this news should mollify investor paranoia that the company would or could have proceeded to Phase 2, let alone Phase 3, in FXS or epilepsy without foundational PK data." (7/5/2018)
Has Zynerba Pharmaceuticals been receiving favorable news coverage?
News coverage about ZYNE stock has been trending somewhat positive this week, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zynerba Pharmaceuticals earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.
Who are some of Zynerba Pharmaceuticals' key competitors?
Some companies that are related to Zynerba Pharmaceuticals include resTORbio (TORC), Aclaris Therapeutics (ACRS), OptiNose (OPTN), Verastem (VSTM), Marker Therapeutics (MRKR), Keryx Biopharmaceuticals (KERX), Stemline Therapeutics (STML), Seres Therapeutics (MCRB), Aratana Therapeutics (PETX), Minerva Neurosciences (NERV), Albireo Pharma (ALBO), Concert Pharmaceuticals (CNCE), Evelo Biosciences (EVLO), Avid Bioservices (CDMO) and BIOFRONTERA AG/ADR (BFRA).
Who are Zynerba Pharmaceuticals' key executives?
Zynerba Pharmaceuticals' management team includes the folowing people:
- Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 60)
- Ms. Terri B. Sebree, Pres (Age 60)
- Mr. James E. Fickenscher, CFO & VP of Corp. Devel. (Age 54)
- Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 49)
- Ms. Suzanne M. Hanlon, Sec., VP of HR & Gen. Counsel (Age 61)
When did Zynerba Pharmaceuticals IPO?
(ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.
Who are Zynerba Pharmaceuticals' major shareholders?
Zynerba Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.69%), BlackRock Inc. (1.69%), Pennsylvania Trust Co (1.15%), Point72 Asset Management L.P. (0.43%), Engineers Gate Manager LP (0.38%) and Jane Street Group LLC (0.20%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, John P Butler, Michael Rapp and Terri B Sebree. View Institutional Ownership Trends for Zynerba Pharmaceuticals.
Which major investors are buying Zynerba Pharmaceuticals stock?
ZYNE stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Point72 Asset Management L.P., BlackRock Inc., Engineers Gate Manager LP, Pennsylvania Trust Co, Zeke Capital Advisors LLC, GSA Capital Partners LLP and Thompson Siegel & Walmsley LLC. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher, John P Butler, Michael Rapp and Terri B Sebree. View Insider Buying and Selling for Zynerba Pharmaceuticals.
How do I buy shares of Zynerba Pharmaceuticals?
Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zynerba Pharmaceuticals' stock price today?
One share of ZYNE stock can currently be purchased for approximately $4.66.
How big of a company is Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals has a market capitalization of $84.61 million and generates $10,000.00 in revenue each year. The company earns $-32,010,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Zynerba Pharmaceuticals employs 22 workers across the globe.
What is Zynerba Pharmaceuticals' official website?
How can I contact Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]
MarketBeat Community Rating for Zynerba Pharmaceuticals (NASDAQ ZYNE)
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZYNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
